<DOC>
	<DOCNO>NCT00482183</DOCNO>
	<brief_summary>Drug-eluting stent show decrease restenosis , associate increased rate death , compare bare-metal stent . Recently , thiazolidinediones effectively reduce restenosis risk repeat target vessel revascularization . We conduct study compare performance drug-eluting stent bare-metal stent pioglitazone patient type 2 diabetic mellitus .</brief_summary>
	<brief_title>Comparison Between Pioglitazone SES With type2 DM</brief_title>
	<detailed_description>The study prospective cohort trial involve 38 type 2 diabetic patient refer coronary stenting assign either sirolimus-eluting stent group pioglitazone group . Quantitative coronary angiography perform study entry six month follow-up evaluate in-stent late luminal loss percentage luminal diameter rate restenosis . We also analyze major adverse cardiac event 12 month .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Patients type 2 diabetes mellitus receive coronary stenting eligible study . spastic angina pectoris congestive heart failure hepatic dysfunction chronic renal disease recent stroke impair glucose tolerance insulin dependent diabetes mellitus familial hypercholesterolemia thyroid dysfunction adrenal dysfunction intolerance aspirin , ticlopidine , heparin , pioglitazone , stainless steel , contrast material .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Bare metal stent</keyword>
	<keyword>Major adverse cardiac event</keyword>
	<keyword>Pioglitazone</keyword>
	<keyword>Restenosis</keyword>
	<keyword>Sirolimus elute stent</keyword>
</DOC>